OBV/PTV/r

DRUG2 trials

Sponsors

AbbVie

Conditions

Chronic Hepatitis C VirusChronic Hepatitis C Virus InfectionHepatitis C Virus

Phase 2

A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection

CompletedNCT02292719

AbbVieChronic Hepatitis C Virus Infection

Start: 2014-12-19End: 2017-07-14Updated: 2021-07-12

Phase 3

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection

CompletedNCT02707952

AbbVieChronic Hepatitis C Virus, Hepatitis C Virus

Start: 2016-02-22End: 2017-02-09Updated: 2021-07-16

Related Papers

Efficacy and Safety of 8- or 12 Weeks of Glecaprevir/Pibrentasvir in Patients with Evidence of Portal Hypertension

Infectious Diseases and Therapy2022-02-173 citations

Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection

Journal of Gastroenterology2019-03-1319 citations

Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan

Antimicrobial Agents and Chemotherapy2017-11-2749 citations

Drug-Drug Interactions between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir with or without Dasabuvir

Antimicrobial Agents and Chemotherapy2015-11-2420 citations